Neil Davie, Ph.D. is the Head, Late Development, of Cardiovascular, Metabolism, & Pulmonary Hypertension (CVM & PH). He has extensive experience as a drug developer leading projects across multiple therapeutic areas, particularly in specialty/rare diseases with high unmet medical need.
Neil joined Janssen in 2019 and is responsible for research and development within the Janssen PH portfolio. This includes drug discovery and external innovation.
Prior to joining Janssen, Neil worked at UCB Pharma as Development Lead. He also spent five years at Bayer as VP of Clinical Development.
Neil obtained his Bachelor of Science in Human Biology from the University of Leeds and his Ph.D. in Pulmonary Pharmacology from Imperial College London. He completed a post-doctoral fellowship at the University of Colorado Health Sciences center (Stenmark Lab), in the field of pulmonary hypertension.
He was appointed Assistant Professor of Pediatric Cardiology at the Children’s Hospital in Denver, working in the pulmonary hypertension lab of Dunbar Ivy.